October 18, 2022Open Access
View Full PaperImpact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial
Structured PICO
Does empagliflozin improve decongestion and clinical benefit in patients hospitalized for acute heart failure?
P
Population
Patients hospitalized for acute heart failure (AHF)
I
Intervention
Empagliflozin
O
Outcome
Decongestion and clinical benefit at Day 90surrogate
Initiation of empagliflozin in acute heart failure provides early and sustained decongestion that is associated with clinical benefit at 90 days.
Abstract
Initiation of empagliflozin in patients hospitalized for AHF resulted in an early, effective and sustained decongestion which was associated with clinical benefit at Day 90.
Cite This Study
Biegus et al. (Tue,) studied this question.